Tirzepatide profoundly transforms the relationship with food. From constant ‘food noise’ to an unexpected mental silence, this metamorphosis can be liberating but also destabilizing. Understanding these changes helps integrate them serenely. Before tirzepatide: omnipresent food For many patients with obesity, food occupies a disproportionate place in their mental space. … Read more
Diarrhea and constipation are the most common digestive issues with tirzepatide. Here’s how to manage them daily. Bowel transit disorders are the second most frequent side effect with Mounjaro, after nausea. Approximately 16 to 23% of patients report episodes of diarrhea and 11 to 17% suffer from constipation. These two … Read more
The SURMOUNT-Jr study paves the way for the treatment of severe obesity in adolescents with tirzepatide, showing superior results to any existing treatment. Pediatric obesity is a global public health crisis. In France, approximately 18% of children and adolescents are overweight or obese, with major physical and psychological consequences. The SURMOUNT-Jr study, … Read more
Discontinuing tirzepatide leads to weight regain in the majority of patients. Here are the scientific data and strategies to limit this phenomenon. One of the most important questions for patients on Mounjaro is: what happens when treatment is stopped? Data from the SURMOUNT-4 study and observational studies provide … Read more
Tirzepatide could become the first effective drug treatment for non-alcoholic steatohepatitis (NASH), a disease affecting millions of French people. Non-alcoholic fatty liver disease (NAFLD), and its progressive form, steatohepatitis (NASH), represent one of the greatest silent epidemics of the 21st century. In France, it is estimated that 18 to 25% of … Read more
With tirzepatide, weight loss isn’t just fat. Understanding body composition is essential to optimize your treatment. One of the major concerns during rapid weight loss is the loss of muscle mass. With GLP-1 agonists like tirzepatide, this issue is even more relevant as weight loss … Read more
The SURMOUNT-3 and SURMOUNT-4 studies answer the crucial question: what happens long-term with tirzepatide? One of the main challenges of anti-obesity treatments is long-term weight loss maintenance. The SURMOUNT-3 and SURMOUNT-4 studies, published in 2023 and 2024, provide essential data on the durability … Read more
The SURMOUNT-1 study laid the scientific foundation for the use of tirzepatide in obesity. A detailed analysis of the game-changing results. Published in the New England Journal of Medicine in July 2022, the SURMOUNT-1 study is the pivotal clinical trial that led to the authorization of tirzepatide (Zepbound) for the treatment of obesity. With 2,539 participants … Read more
Tirzepatide does more than just reduce appetite: it simultaneously acts on three vital organs to combat obesity and type 2 diabetes. Tirzepatide, the active ingredient in Mounjaro and Zepbound, is often presented as a simple injectable appetite suppressant. This reductive view ignores the complexity of its mechanism of action. In reality, this … Read more
Tirzepatide Half-Life: How 3 Chemical Modifications Transform a 3-Minute Hormone into a Weekly Treatment. Pharmacokinetics Explained.
How tirzepatide reduces appetite: mechanisms of satiety, food noise, neuronal signals. What patients experience and how to optimize.
Discover the unique mechanism of action of tirzepatide, the first dual GIP/GLP-1 agonist. Learn how Mounjaro acts on the brain, pancreas, liver, and adipose tissue to produce superior weight loss compared to mono-agonists.